ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated human rotavirus rix4414 strain - תרחיף - live attenuated human rotavirus rix4414 strain - rota virus, live attenuated - rota virus, live attenuated - rotarix is indicated for the active immunization of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection. in clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of types g1p[8], g2p[4], g3p[8], g4p[8] and g9p[8]. the use of rotarix should be based on official recommendations.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ribavirin - קפסולות - ribavirin 200 mg - ribavirin - ribavirin - rebetol is indicated for the treatment of chronic hepatitis c and must only be used as part of a combination regimen with peginterferon alfa-2b (adults) or interferon alfa-2b (adults). rebetol monotherapy must not be used. there is no safety or efficacy information on the use of rebetol with other forms of interferon (i.e., not alfa-2b).previously untreated (na?ve) patients rebetol is indicated in adult patients :• in combination with peginterferon alfa-2b or interferon alfa-2b , for the treatment of adult patients with chronic hepatitis c, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna . additionally, rebetol is indicated , in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis c ,not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna including patients with clinically stable hiv co-infection. pre

ישראל - עברית - Ministry of Health

sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - תרחיף להזרקה - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - ribavirin 200 mg - tablets - ribavirin - copegus in combination with peginterferon alfa 2a or interferon alfa - 2a is indicated in adult patients who are positive for serum hcv-rna, including patients with compensated cirrhosis . the combination with peginterferon alfa-2a is also indicated in patients co-infected with clinically stable hiv , including patients with compensated cirrhosis . copegus, in combination with peginterferon alfa-2a, is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin.

ישראל - עברית - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - תרחיף להזרקה - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.

ישראל - עברית - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b

ישראל - עברית - Ministry of Health

מדיסון פארמה בע"מ - מומחה - פרוצדורת רוטבלייטור

ישראל - עברית - Ministry of Health

medici ltd - diphtheria toxoid 2 iu / 0.5 ml; poliomyelitis virus type 1 40 du/dose - suspension for injection - diphtheria-poliomyelitis-tetanus - this combined vaccine is indicated for adults as a booster of a previous vaccination for the simultaneous prevention of diphtheria tetanus and poliomyelitis. refer to the official recommendations for vaccination schedules. this vaccine may be administered as a booster of a previous vaccination to children 6 or older in exceptional cases particularly in the case of a shortage of the diphtheria tetanus and poliovirus vaccine (dtpolio) recommended in the vaccination schedule.